Cellectis S.A. Stock News

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)

Allogene: Speculative CAR T Biotech With Big Potential In Oncology

The FDA has signed off Iovance Biotherapeutics Inc''s (NASDAQ: IOVA ) Investigational New Drug Application (IND) first genetically modified TIL therapy, IOV-4001, for unresectable or metastatic melanoma and stage III or IV non-small-cell lung cancer (NSCLC). IOV-4001 leverages the gene-editing TALEN technology licensed from Cellectis SA (NASDAQ: Full story available on Benzinga.com

Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages TALEN® technology Licensed from Cellectis to Inactivate PD-1 Expression SAN CARLOS, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC. IOV-4001 leverages the gene editing TALEN® technology licensed from Cellectis (NASDAQ: CLLS ), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop potentially life-saving cell and gene therapies, to inactivate the gene coding for the PD-1 protein.

Cellectis S.A. (NASDAQ:CLLS) shares, rose in value on Friday, 03/11/22, with the stock price up by 4.76% to the previous day’s close as strong demand from buyers drove the stock to $4.40. Actively observing the price movement in the last trading, the stock closed the session at $4.20, falling within a range of $4.34 and … Cellectis S.A. (NASDAQ: CLLS) Up 4.76%: This Is What Analysts Now Expect Read More »

NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to

French clinical-stage biotechnological company, Cellectis <> is trading higher for the fourth consecutive session on Friday as the market reacts to the Fast Track designation…

Clearside Biomedical CLSD +38%. Cellectis (CLLS) +13%. Orphazyme ORPH -37%. Aesthetic Medical International (AIH) -19%.

NEW YORK , March 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXN, CLLS, SDPI, SFET, and DS. … Full story available on Benzinga.com

Investors saw a bargain when the stock hit its 52-week low early in the week.

Investors saw a bargain when the stock hit its 52-week low early in the week.

Cellectis S.A. (CLLS) CEO Andre Choulika on Q4 2021 Results - Earnings Call Transcript

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop potentially life-saving cell and gene therapies, announced its results for the fourth quarter of 2021, and full year ending December 31, 2021.

Cellectis press release (CLLS): Q4 GAAP EPS of -$0.18.Revenue of $1.94M (-86.0% Y/Y).The company said the decrease was driven by lower volumes of product sold in 2021 as it…

Cellectis (NASDAQ:CLLS) is scheduled to announce Q4 earnings results on Thursday, March 3rd, after market close.The consensus EPS Estimate is -$0.88 (-166.7% Y/Y) and the consensus…